[go: up one dir, main page]

ES2109377T3 - Proceso para la preparacion de una dispersion solida. - Google Patents

Proceso para la preparacion de una dispersion solida.

Info

Publication number
ES2109377T3
ES2109377T3 ES92925333T ES92925333T ES2109377T3 ES 2109377 T3 ES2109377 T3 ES 2109377T3 ES 92925333 T ES92925333 T ES 92925333T ES 92925333 T ES92925333 T ES 92925333T ES 2109377 T3 ES2109377 T3 ES 2109377T3
Authority
ES
Spain
Prior art keywords
drug
preparation
solid dispersion
polymer
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92925333T
Other languages
English (en)
Inventor
Isaac Ghebre-Sellassie
Robert Reisch Jr
Riten Parikh
Mahdi B Fawzi
Russell U Nesbitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2109377T3 publication Critical patent/ES2109377T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Glanulating (AREA)
  • Ceramic Products (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

UNA NUEVA DISPERSION SOLIDA FARMACEUTICA QUE MEJORE LA BIODISPONIBILIDAD DE FARMACOS QUE SE DISUELVEN MAL EN AGUA SE PRODUCE A BASE DE COMBINAR EL FARMACO CON UN SOPORTE POLIMERICO TAL COMO POLIVINILPIRROLIDONA. SI SE UTILIZA UN COMPUESTO DE TRANSICION TAL COMO POLIETILENGLICOL, QUE SOLUBILIZA PARCIALMENTE EL FARMACO Y/O PLASTIFICA EL POLIMERO, NO ES NECESARIA LA UTILIZACION DE SOLVENTES ORGANICOS NI DE TEMPERATURAS DE DERRETIMIENTO (FUSION) AL COMBINAR EL FARMACO CON EL SOPORTE.
ES92925333T 1991-12-18 1992-11-18 Proceso para la preparacion de una dispersion solida. Expired - Lifetime ES2109377T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80965691A 1991-12-18 1991-12-18

Publications (1)

Publication Number Publication Date
ES2109377T3 true ES2109377T3 (es) 1998-01-16

Family

ID=25201894

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92925333T Expired - Lifetime ES2109377T3 (es) 1991-12-18 1992-11-18 Proceso para la preparacion de una dispersion solida.

Country Status (17)

Country Link
US (3) US6677362B1 (es)
EP (1) EP0617612B1 (es)
JP (1) JP3722293B2 (es)
AT (1) ATE157864T1 (es)
AU (1) AU671811B2 (es)
CA (1) CA2124821C (es)
DE (1) DE69222182T2 (es)
DK (1) DK0617612T3 (es)
ES (1) ES2109377T3 (es)
GR (1) GR3025501T3 (es)
IL (1) IL104179A (es)
MX (1) MX9207390A (es)
NZ (1) NZ245483A (es)
PT (1) PT101132B (es)
SG (1) SG43179A1 (es)
WO (1) WO1993011749A1 (es)
ZA (1) ZA929789B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
ES2109377T3 (es) 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
WO1995013794A1 (en) * 1993-11-18 1995-05-26 Nippon Shinyaku Co., Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
SE9502244D0 (sv) * 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AU3508097A (en) 1996-06-26 1998-01-14 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
AU3483497A (en) * 1996-06-28 1998-01-21 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
HN1998000115A (es) * 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
US6376542B1 (en) * 1997-12-19 2002-04-23 Bissell Homecare, Inc. Aqueous miticide compositions containing benzyl benzoate
US6107341A (en) * 1997-12-19 2000-08-22 Bissell Homecare, Inc. Aqueous miticide containing benzyl benzoate
PT1039908E (pt) * 1997-12-22 2004-06-30 Schering Corp Composicao de dispersao molecular com biodisponibilidade melhorada
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
EP1183017A1 (en) * 1999-05-28 2002-03-06 Abbott Laboratories Novel formulations comprising lipid-regulating agents
DE19929361A1 (de) * 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
SK15732003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
EP1469832B2 (en) * 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
CN1622810A (zh) * 2002-03-14 2005-06-01 华生制药公司 孕酮口服药物传输系统
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
KR20050045946A (ko) 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
US8486447B2 (en) * 2003-02-03 2013-07-16 Novartis Ag Pharmaceutical formulation
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
CA2523883C (en) * 2003-04-29 2012-01-03 Akzo Nobel N.V. Antisolvent solidification process
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8273371B2 (en) 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1680091B1 (en) 2003-10-10 2017-05-31 Veloxis Pharmaceuticals A/S A solid dosage form comprising a fibrate
AU2004294817B2 (en) * 2003-12-04 2007-01-25 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
EP1871346A4 (en) * 2005-04-20 2012-07-18 Ctc Bio Inc PHARMACEUTICAL COMPOSITION WITH FREE BASE FROM SIBUTRAMIN AND MANUFACTURING METHOD THEREFOR
DE102005023803A1 (de) * 2005-05-19 2006-11-23 Basf Ag Verfahren zur Herstellung von festen Blends aus Polyvinylpyrrolidonen und ethoxilierten Fettsäurederivaten
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
WO2008079629A2 (en) * 2006-12-21 2008-07-03 Boehringer Ingelheim International Gmbh Formulations with improved bioavailability
AU2009203627A1 (en) * 2008-01-11 2009-07-16 Cipla Limited Solid pharmaceutical dosage form
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
PT2273983T (pt) 2008-05-09 2016-10-28 Gruenenthal Gmbh Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
PE20120572A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
UA110199C2 (xx) * 2009-10-27 2015-12-10 Lupin Ltd Тверда дисперсія рифаксиміну
AU2011297892B2 (en) 2010-09-02 2014-05-29 Grunenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
ES2571735T3 (es) 2010-10-20 2016-05-26 Dsm Ip Assets Bv Composiciones biodegradables que soportan grupo hidrófilo colgante y dispositivos relacionados
SG10201801794WA (en) * 2010-10-29 2018-04-27 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
MX348054B (es) 2011-07-29 2017-05-25 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
NO2736495T3 (es) 2011-07-29 2018-01-20
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
WO2016089796A1 (en) * 2014-12-04 2016-06-09 Merck Sharp & Dohme Corp. Formulation inhibiting effects of low acid environment
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
CN113616599B (zh) * 2021-09-10 2022-11-18 宁夏医科大学 一种大黄素固体分散体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0083370A1 (en) * 1981-07-08 1983-07-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
DE3839825A1 (de) * 1988-11-25 1990-06-13 Henning Berlin Gmbh Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
ES2109377T3 (es) 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.

Also Published As

Publication number Publication date
JP3722293B2 (ja) 2005-11-30
GR3025501T3 (en) 1998-02-27
EP0617612B1 (en) 1997-09-10
DE69222182T2 (de) 1998-02-26
US6677362B1 (en) 2004-01-13
PT101132B (pt) 2000-02-29
MX9207390A (es) 1993-06-01
WO1993011749A1 (en) 1993-06-24
DK0617612T3 (da) 1998-04-14
DE69222182D1 (de) 1997-10-16
SG43179A1 (en) 1997-10-17
ATE157864T1 (de) 1997-09-15
NZ245483A (en) 1995-12-21
IL104179A0 (en) 1993-05-13
CA2124821A1 (en) 1993-06-24
JPH07504162A (ja) 1995-05-11
US20010044409A1 (en) 2001-11-22
AU671811B2 (en) 1996-09-12
AU3142693A (en) 1993-07-19
EP0617612A1 (en) 1994-10-05
US20040110694A1 (en) 2004-06-10
CA2124821C (en) 2003-10-07
ZA929789B (en) 1993-06-23
PT101132A (pt) 1994-03-31
IL104179A (en) 1997-11-20

Similar Documents

Publication Publication Date Title
ES2109377T3 (es) Proceso para la preparacion de una dispersion solida.
DE59009074D1 (de) Diarylsubstituierte heterocyclische Verbindung, ihre Herstellung und Arzneimittel und Kosmetika daraus.
ATE67930T1 (de) Wirkstofftraeger und diesen enthaltende arzneimittel.
DE69430237D1 (de) Arzneimittel zur gesteuerten Freisetzung
NO890075L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazoler.
DE3689983D1 (de) Arzneimittel mit langsamer Wirkstofffreisetzung.
NL300206I1 (nl) R-enantiomeer van N-propargyl-1-aminoindaan, de bereiding daarvan en farmaceutische preparaten die dit bevatten.
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
ATE116843T1 (de) Lösungsmittelfreie, oral zu verabreichende pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung und verfahren zu deren herstellung.
RU93036959A (ru) Свободно растворимый лекарственный препарат с замедленным действием биологически активных веществ, назначенный для приема внутрь, способ его производства
ATE104300T1 (de) Thieno(2,3-d>azepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DK1151746T3 (da) Mikro-kapsler til vedvarende frigivelse af lægemidler
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung
RU94032148A (ru) Нафтоксазины и способ их получения, их применение для производства медикаментов и содержащая их фармацевтическая композиция
NO160258C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive pyridazinonimin-derivater.
ATE75746T1 (de) Cephalosporinderivate und verfahren zu ihrer herstellung.
ATE181828T1 (de) Oral anzuwendendes arzneimittel bestehend aus ibuprofen
DK22983A (da) Fremgangsmaade til fremstilling af penicillinderivater
FR2767132B1 (fr) Nouveaux composes de bis pyrido [4,3-b] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU94029664A (ru) Новые производные 11-бензальдоксимэстра-4-9-диена, способ их получения и содержащие эти соединения лекарственные средства
RU93058142A (ru) Производные хинолина, способ их получения, фармацевтическая композиция и способ лечения
IT1228569B (it) Derivati dell'indolo, procedimento per la loro preparazione e mezzi farmaceutici contenenti tali composti.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 617612

Country of ref document: ES